Femasys Inc.

FEMY

US31447E1055

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-06 pm EST			5-day change	1st Jan Change
0.5080 ^USD	+4.74%		-5.08%	-11.84%

Feb. 03	Femasys Inc. Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products	CI
Jan. 14	Femasys granted 180-day extension by Nasdaq to regain compliance with minimum bid price requirement	RE

Top Midday Gainers

Published on 09/29/2023 at 01:45 pm EDT - Modified on 09/29/2023 at 01:46 pm EDT

MT Newswires

Latest news about Femasys Inc.

Feb. 03	Femasys Inc. Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products	CI
Jan. 14	Femasys granted 180-day extension by Nasdaq to regain compliance with minimum bid price requirement	RE
Jan. 13	Femasys Inc. Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed®? in Community-Based Care	CI
Jan. 13	Femasys announces partnership with Refuah Health Center to expand first-line access to FemaSeed® in community-based care	RE
Dec. 18	Femasys Inc. Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device	CI
Dec. 18	Femasys secures U.S. FDA clearance for next-generation Femvue diagnostic device	RE
Nov. 14	Femasys Q3 sales rise, driven by FemBloc sales	RE
Nov. 14	Femasys Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 10	Femasys Advances Global Growth with Second Partner Order for FemBloc in Europe	CI
Nov. 03	Femasys Secures Fda Approval to Advance Final Fembloc Trial Phase and $12 Million Financing, with Potential to Reach $58 Million	CI
Nov. 03	Femasys Inc. announced that it expects to receive $12 million in funding	CI
25-10-24	Certain Warrants of Femasys Inc. are subject to a Lock-Up Agreement Ending on 25-OCT-2025.	CI
25-10-24	Certain Options of Femasys Inc. are subject to a Lock-Up Agreement Ending on 25-OCT-2025.	CI
25-10-24	32,575,407 Common Stock of Femasys Inc. are subject to a Lock-Up Agreement Ending on 25-OCT-2025.	CI
25-10-22	Femasys Inc. Announces Initiation of Post-Market Surveillance Study for Fembloc Permanent Birth Control in Europe	CI
25-10-17	Femasys Inc. Announces Retirement of Daniel Currie as Chief Operating Officer, Effective as of December 15, 2025	CI
25-09-25	Femasys Inc. Accelerates European Growth for FemBloc® with Kebomed Partnership	CI
25-09-22	Femasys Inc. Partners with Medical Electronic Systems LLC to Launch FemSperm?? Analysis Kit for Use with FemaSeed	CI
25-09-11	Femasys Inc. Expands FemSperm?? Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemSeed	CI
25-09-08	Femasys Secures Regulatory Approval for Fembloc Permanent Birth Control in New Zealand	CI
25-09-08	Femasys secures regulatory approval for FemBloc permanent birth control in New Zealand	RE
25-09-02	Femasys Raises $8 Million to Advance Reproductive Health Products	MT
25-09-02	Femasys closes $8 million in financing to accelerate commercialization of fertility and birth control portfolios	RE
25-08-26	Top Midday Decliners	MT
25-08-26	Femasys Prices $8 Million Public Offering; Shares Slump Pre-Bell	MT

Femasys Inc. is a biomedical company. The Company is focused on addressing unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The Company also developed a technology platform, namely FemEMB for tissue sampling intended to be marketed alongside its other women-specific medical products in the physicianâ€™s office setting.

Employees

Sector

Medical Equipment, Supplies & Distribution

Calendar

Mar. 25 - Q4 2025 Earnings Release (Projected)

More about the company